Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study

Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study

Abstract Background Monoclonal antibodies (mABs) targeting the calcitonin gene-related peptide (CGRP) pathway represent the first disease-specific preventive migraine therapy. Growing evidence suggests that they are effective in the preventive treatment of difficult-to-treat patients. In this study,...

Full description

Bibliographic Details
Main Authors: Bottiroli Sara, Roberto De Icco, Gloria Vaghi, Stefania Pazzi, Elena Guaschino, Marta Allena, Natascia Ghiotto, Daniele Martinelli, Cristina Tassorelli, Grazia Sances
Format: Article
Language:English
Published: BMC 2021-10-01
Series:The Journal of Headache and Pain
Subjects:
Anti-CGRP monoclonal antibody
Open label
Chronic migraine
Personality
Anxiety
Stressful event
Online Access:https://doi.org/10.1186/s10194-021-01333-4

Internet

https://doi.org/10.1186/s10194-021-01333-4

Similar Items